Relapsed Refractory Multiple Myeloma (RRMM), Daratumumab+Pomalidomide+Dexamethasone (DPd), Pomalidomide+Dexamethasone (Pd), 1,2,3,>=4 prior line of therapy, Anti-CD38 MAb, Phase 3, Lenalidomide Exposed
### Instruction:
Identify the study with the following condition. 
### Input:
Relapsed Refractory Multiple Myeloma (RRMM), Daratumumab+Pomalidomide+Dexamethasone (DPd), Pomalidomide+Dexamethasone (Pd), 1,2,3,>=4 prior line of therapy, Anti-CD38 MAb, Phase 3, Lenalidomide Exposed 
### Output:
Popular Name is APOLLO, Study ID is NCT03180736